Table 6.
Selected clinical trials that incorporate immune checkpoint inhibitors in experimental therapy of NHL.
| Drug Combination | Mode of Action of the Combination Agent(s) Other Than Immune Checkpoint Inhibitors | Study Phase | Disease Status | Estimated Study Completion Date | ClinicalTrials.gov Identifier (Other Identifier) |
|---|---|---|---|---|---|
| Nivolumab + R(ituximab)-GemOx compared to R-GemOx | immunochemotherapy gemcitabine + oxaliplatin (GemOx) | 2/3 | R/R elderly B-NHL | November 2024 | NCT03366272 (NIVEAU) |
| Avelumab +/− Utomilumab +/− Rituximab +/− Azacitidine +/− bendamustin +/− Gemcitabine +/− Oxaliplatine | CD137 (4-1BB) antigen agonist antibody utomilumab, anti-CD20 antibody rituximab, epigenetic modulator azacitidine, conventinal chemotherapy GemOx | 1/3 | R/R DLBCL | December 2019 | NCT02951156 (JAVELIN DLBCL) |
| Nivolumab + DA-EPOCH-R + Nivolumab as a consolidation | immunochemotherapy regimen (dose-adjusted EPOCH-R) | 2 | B-NHL | December 2021 | NCT03749018 |
| Nivolumab + Copanlisib | pan-PI3K inhibitor copanlisib | 2 | R/R DLBCL, PMBCL | October 2021 | NCT03484819 |
| Pembrolizumab | 2 | untreated B-NHL | September 2024 | NCT03498612 | |
| Pembrolizumab | 2 | R/R grey-zone lymphoma, R/R PCNSL, R/R DLBCL | July 2022 | NCT03255018 | |
| Pembrolizumab + R-CHOP | R-CHOP immunochemotherapy regimen | 2 | DLBCL, high-grade B-NHL | August 2024 | NCT03995147 |
| Pembrolizumab + Rituximab +/− Lenalidomide | anti-CD20 antibody, immunomodulatory agent lenalidomide | 2 | R/R FL, R/R DLBCL | November 2021 | NCT02446457 |
| Durvalumab + R-CHOP/R2-CHOP | standard immunochemotherapy, immunomodulatory agent lenalidomide | 2 | DLBCL | March 2023 | NCT03003520 |
| Ipilimumab + Lenalidomide | immunomodulatory agent lenalidomide | 2 | NHL (post-HSCT) | June 2021 | NCT01919619 |
| Pembrolizumab + ALX-148 | CD47 antagonist ALX-148 | 1 | NHL, solid tumors | December 2021 | NCT03013218 |
Abbreviations: B-NHL= B cell non-Hodgkin lymphomas; CHOP= cyclophosphamide + doxorubicin + vincristine + prednisone; DLBCL= diffuse large B-cell lymphoma; EPOCH-R= etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab; FL= follicular lymphoma; HSCT= hematopoietic stem cell transplantation; PCNS= primary CNS lymphoma; PMBCL= primary mediastinal B-cell lymphoma; R/R= relapsed/refractory.